Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
The main objective of this research is to increase the life expectancy of patients with advanced mouth and throat cancer, by adding avelumab to the standard TPEx treatment.
- Trial name
- TATIANA (NCT06640725)
- Testing
- Avelumab administration at 10mg/kg, Cetuximab (Erbitux)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Squamous Cell Carcinoma of the Oropharynx
Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
The curative treatment and organ preservation in advanced squamous cell carcinoma of the oropharynx is multimodal. It involves induction chemotherapy and depending on the response radio-chemotherapy or surgery.
- Trial name
- NCT02552550
- Testing
- Ability to swallow, speak and quality of life
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Head and Neck Cancer
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways and combining it with chemotherapy before surgery may kill more tumor cells.
- Trial name
- NCT00047008
- Testing
- cisplatin, Standard fractionation RT, Accelerated fractionation radiation therapy
- Where
- 195 sites in United States
- Volunteers
- 743 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Cancer
Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
Definitive chemoradiation is the standard treatment for locally advanced esophageal cancer. NCCN (National Comprehensive Cancer Network) recommends radiation dose of 50-50.4 Gy as the definitive radiation dose for esophageal…
- Trial name
- NCT02850991
- Testing
- High-dose, Standard-dose
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Reconstruction
A single-institution, randomize controlled trial is to be held to evaluate the correlation between blood supply in the gastic conduit and the incidence of anastomotic fistula during radical operation for esophageal squamous cell…
- Trial name
- NCT04229524
- Testing
- Fluorescence angiography
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Squamous Cell Carcinoma
Cetuximab and Lenalidomide in Head and Neck
The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide.
- Trial name
- NCT01133665
- Testing
- Cetuximab and Lenalidomide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Chicago
Head and Neck Cancer
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
The purpose of this study is to define the response and toxicities with the addition of Nimotuzumab to chemoradiation for head and neck cancer.
- Trial name
- NCT00702481
- Testing
- Nimotuzumab, Cisplatin, Radiation
- Where
- Singapore
- Volunteers
- 32 people
- Sponsor
- National Cancer Centre, Singapore
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
The main purpose of this research study is to collect information to learn how effective erlotinib (tarceva) is in combination with either bevacizumab or sulindac in treating patients with squamous cell carcinoma of the head and…
- Trial name
- NCT00392665
- Testing
- Bevacizumab, erlotinib, Sulindac
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Head and Neck Squamous Cell Carcinoma
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing schedules of cemiplimab given in combination with cisplatin and docetaxel induction chemotherapy (TPI) in patients with locally advanced…
- Trial name
- NCT05376553
- Testing
- Cemiplimab, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Krzysztof Misiukiewicz
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharynx (OPX) Biomarker Trial
The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06356272
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Mayo Clinic
Squamous Cell Carcinoma of Head and Neck
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.
- Trial name
- NCT05845307
- Testing
- Control Group, TTI-101
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinomas
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who…
- Trial name
- NCT05724329
- Testing
- Tislelizumab + Dasatinib + Quercetin (neoadjuvant), surgery, Tislelizumab + Dasatinib + Quercetin (adjuvant)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Neoplasms, Hearing Disorder
Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation
Background: Cisplatin is a chemotherapy drug. It is used to treat head and neck squamous cell carcinoma (HNSCC) and other cancers. It can cause hearing loss for some people.
- Conditions
- Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
- Trial name
- NCT03225157
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Esophageal Squamous Cell Carcinoma
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced esophageal squamous cell carcinoma progressed following treatment with…
- Trial name
- NCT03817567
- Testing
- recombinant anti-EGFR monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sinocelltech Ltd.
Breast Cancer, Glioblastoma
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors.
- Conditions
- Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma
- Trial name
- NCT05538572
- Testing
- PRT3645
- Where
- 13 sites in United States, Singapore
- Volunteers
- 22 people
- Sponsor
- Prelude Therapeutics Incorporated
Head and Neck Squamous Cell Carcinoma
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
A Randomized, Non-comparative Phase II Clinical Trial of Becotatug Vedotin Combined with or without Immune Checkpoint Inhibitors (Penpulimab/Ivonescimab) in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck…
- Trial name
- NCT07381075
- Testing
- Becotatug Vedotin, Becotatug Vedotin Combined with Penpulimab, Becotatug Vedotin Combined with Ivonescimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- West China Hospital
Oral Mucositis
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
The purpose of the phase 3, clinical study is to determine if GC4419 (avasopasem manganese) administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients…
- Trial name
- NCT03689712
- Testing
- GC4419 90mg
- Where
- 97 sites in United States, Canada and 1 more
- Volunteers
- 455 people
- Sponsor
- Galera Therapeutics, Inc.
Head and Neck Squamous Cell Carcinoma
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2
This is a single-centre feasibility study designed to assess the safety, tolerability and engraftment of MET-4 bacterial strains when given in combination with chemoradiotherapy (CRT).
- Trial name
- ROMA LA-OPSCC2 (NCT03838601)
- Testing
- MET-4
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma
- Trial name
- NCT00805012
- Testing
- docetaxel+CDDP, docetaxel+S-1
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.